Vanguard Group Inc Now Holds $214.3 million Worth Of Intercept Pharmaceuticals, Inc. (ICPT)

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) went up to recover about 114.95% since recording its record low price of $51.05. The stock experienced -2.88% slump, arriving at $109.73 on 01/11/2019. During the day, the stock price traveled from $109.3341 to $112.78. This company shares are 26.53% off its target price of $138.84 and the current market capitalization stands at $3.35B. The recent change has given its price a 5.42% lead over SMA 50 and -17.95% deficit over its 52-week high. The stock witnessed 4.91% gains, 7.49% gains and 13.44% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ICPT’s volatility during a week at 4.18% and during a month it has been found around 6.18%.

Intercept Pharmaceuticals, Inc. (ICPT) Top Holders

Institutional investors currently hold around $2.07 billion or 65.5% in ICPT stock. Look at its top three institutional owners. Fmr Llc owns $486.62 million in Intercept Pharmaceuticals, Inc., which represents roughly 14.53% of the company’s market cap and approximately 23.46% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 2,110,651 shares of the stock are valued at $231.6 million. The third largest holder is Vanguard Group Inc, which currently holds $214.3 million worth of this stock and that ownership represents nearly 6.4% of its market capitalization.

Intercept Pharmaceuticals, Inc. 13F Filings

At the end of September reporting period, 86 institutional holders increased their position in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) by some 1,955,080 shares, 80 decreased positions by 3,662,722 and 32 held positions by 13,279,917. That puts total institutional holdings at 18,897,719 shares, according to SEC filings. The stock grabbed 35 new institutional investments totaling 240,417 shares while 25 institutional investors sold out their entire positions totaling 1,312,353 shares.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Insider Trades

Multiple company employees have indulged in significant insider trading. Intercept Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President, International Bright Lisa has sold 1,313 shares of Intercept Pharmaceuticals, Inc. (ICPT) in trading session dated Jan. 07, 2019. These shares are worth $137,773 and were traded at $104.93 each. The SEC filing shows that Shapiro David performed a sale of 474 shares. The Chief Medical Officer disposed these shares by way of transaction on Jan. 04, 2019. The company’s shares were given away at $97.48 per share worth to an income of some $46,206 on account of Shapiro David.

Chief Medical Officer, Shapiro David, sold 2,699 common shares of Intercept Pharmaceuticals, Inc. (ICPT) in the open market. In a transaction dated Jan. 03, 2019, the shares were put up for sale at an average price of $98.07, raking in a sum of $264,691. After this sale, 37,717 common shares of ICPT are directly owned by the insider, with total stake valued at $4,138,686.

In the transaction dated Dec. 17, 2018, the great number of shares disposed came courtesy the Chief Medical Officer; Shapiro David disposed a total of 2,000 shares at an average price of $106.62, amounting to approximately $213,240. The insider now directly owns 39,152 shares worth $4,296,149.

Intercept Pharmaceuticals, Inc. (ICPT) Analyst Guide

Several analysts have released their opinion on Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), with 3 analysts believing it is a strong buy. Whereas 7 of them predict the stock is a hold. Also, there are 6 buy, 1 sell and 0 strong sell ratings, collectively assigning a 2.35 average brokerage recommendation.